Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly's Retevmo lands new accelerated approval for pediatric cancers
Details : Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with CNS activity, which is investigated for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer.
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chugai Gets Approval for FoundationOne CDx as Companion Diagnostic for RET Inhibitor
Details : Retevmo (selpercatinib) is an oral RET receptor tyrosine kinase inhibitor, small molecule drug candidate which is indicated for the treatment of RET fusion-positive solid tumors.
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity, which is investigated for the treatment of advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid canc...
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2023
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity, which is used for the treatment of Adults with Newly-Diagnosed Advanced or Metastatic RET fusion-positive non-small Cell lung cancer...
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2023
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the LIBRETTO-001 trial, Retevmo (selpercatinib) demonstrated clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers, including pancreatic, colon and other cancers in need of new treatment option...
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Twenty-six patients had measurable central nervous system metastases at baseline and treatment with Retevmo resulted in a CNS ORR of 84.6%, with 22 patients having a confirmed best response of complete response or partial response.
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2022
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Loxo Oncology Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising antitumour activity and safety in various RET fusion-positive advanced solid tumours. Safety consistent with known profile of Retevmo.
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2021
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Loxo Oncology Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly's Cancer Drug Retsevmo Gets UK Approval for Multiple Indications
Details : The agency approved selpercatinib for the treatment of adults with advanced RET fusion positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Product Name : Retsevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2021
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy
Details : Retevmo™ (selpercatinib) has been approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer.
Product Name : Retevmo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable